Chinese Company Refuses GMP Inspection and Gets an Import Alert from the FDA

Recommendation
22/23 October 2025
Barcelona, Spain
The US FDA has placed the Chinese company Beijing Shunxin Meihua Bio-technical Co on an import alert. Consequently, the company cannot deliver any product to the US market. According to the information portal Regulatory Focus, the import alert was published on 22 July 2014. Last year, the FDA referred to its competence in a Guideline and emphasised the fact that any refusal or obstruction to an inspection would have immediate consequences. You can read more on the topic in our GMP News "Denying, Delaying, And Refusing: How to Fail a FDA Inspection". Already in the past, a Chinese company got a Warning Letter after it had thrown three FDA inspectors out of the facility.
Related GMP News
14.10.2025Two new GDP Non-Compliance Reports from Romania
01.10.2025Alternative Inspection Methods of the FDA
24.09.2025FDA issues final Guidance on Remote Oversight Tools
24.09.2025Four Warning Letter concerning CAPA and Root Cause Analysis published
03.09.2025FDA Report on the State of Pharmaceutical Quality
27.08.2025Bizarre Findings in FDA Warning Letters